שווי מתואם לחוב ומזומנים: Amarin Corporation plc (AMRN)

This chart illustrates that the market value of Amarin Corporation plc (AMRN) is -49.78, with the business relying on the supply of omega-3 fatty acid cardiovascular drugs and utilizing a European network of plants for stability. However, the expansion of affordable generics has stripped the company of its pricing power, reducing profitability. The situation is further complicated by a slow product portfolio refresh, creating significant risks due to over-reliance on a single drug.

The evolution of Amarin Corporation plc (AMRN) enterprise value reflects the market's valuation of the company, accounting for the risks of losing patent protection for Vascepa and its debt load. This metric is calculated as the sum of market capitalization and liabilities minus cash, determining the actual price for a full buyout of the asset, which is critical for assessing the resilience of a biopharmaceutical business amidst fierce generic competition.